Efficacy and safety of the first targeted biological drug dupilumab in the treatment of severe continuously relapsing atopic dermatitis

Abstract

In the past few decades, the prevalence of allergic dermatoses in European countries, including the Russian Federation, has increased two to three times. The skin barrier plays an essential role in preventing the penetration of allergens and microbial agents into the human body. Atopic dermatitis is one of the most common, genetically determined skin diseases. The development of atopic dermatitis involves environmental factors that violate the skin barrier, as well as the genetic, immunological characteristics of the patient. In modern science, the issue of pathogenetic treatment of atopic dermatitis remains not fully resolved. The problem is compounded by the fact that this disease is multifactorial, with a predominance of IgE-mediated allergic reactions, although the level of IgE does not always correlate with the severity of atopic dermatitis. Currently, the development and implementation of genetically engineered drugs for the treatment of this pathology continues, one of these drugs is dupilumab. The article describes the efficacy and safety of dupilumab in the treatment of severe continuously relapsing atopic dermatitis.